Cirena licenses Agilent RNA purification tech to unlock high-purity long RNA for genome editing
The agreement targets a long-standing technical hurdle in the field: maintaining chemical purity as RNA constructs extend beyond 100 nucleotides
The agreement targets a long-standing technical hurdle in the field: maintaining chemical purity as RNA constructs extend beyond 100 nucleotides
The center brings together hands on technology demonstrations, application expertise, and commercial operations
The FDA approval makes PD-L1 IHC 22C3 pharmDx the only companion diagnostic approved to detect tumors expressing PD-L1 in esophageal or GEJ carcinoma patients for KEYTRUDA treatmen
The acquisition of Biocare enhances Agilent’s pathology portfolio and reflects our strategy to drive long-term growth
This approval represents the seventh FDA-approved companion diagnostic indication for PD-L1 IHC 22C3 pharmDx with KEYTRUDA
The center will deliver Certified Pre-Owned instruments restored to factory-grade standards and backed by Agilent Standard Warranty
The collaboration will establish the MUMPMP–Agilent BioDiscovery Hub
Collaboration combines Lunit's AI expertise with Agilent's diagnostic leadership to revolutionize biomarker testing and enhance precision medicine capabilities
Integrated facility to deliver end-to-end, customized workflows across life sciences, diagnostics, and applied markets
Subscribe To Our Newsletter & Stay Updated